These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18420190)

  • 1. Behavioural genetics in mood and anxiety: a next step in finding novel pharmacological targets.
    de Mooij-van Malsen AJ; Olivier B; Kas MJ
    Eur J Pharmacol; 2008 May; 585(2-3):436-40. PubMed ID: 18420190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
    Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lost in translation. New unexplored avenues for neuropsychopharmacology: epigenetics and microRNAs.
    Tardito D; Mallei A; Popoli M
    Expert Opin Investig Drugs; 2013 Feb; 22(2):217-33. PubMed ID: 23253113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does neuropeptide Y (NPY) mediate the effects of psychotropic drugs?
    Obuchowicz E; Krysiak R; Herman ZS
    Neurosci Biobehav Rev; 2004 Oct; 28(6):595-610. PubMed ID: 15527865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Psychological and pharmacological treatments of mood and anxiety disorders during pregnancy and postpartum. Review and synthesis].
    Dayan J; Yoshida K
    J Gynecol Obstet Biol Reprod (Paris); 2007 Oct; 36(6):530-48. PubMed ID: 17616265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders.
    Serretti A; Chiesa A; Calati R; Perna G; Bellodi L; De Ronchi D
    Int Clin Psychopharmacol; 2009 Jan; 24(1):1-18. PubMed ID: 19060722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression.
    O'Connor RM; Dinan TG; Cryan JF
    Mol Psychiatry; 2012 Apr; 17(4):359-76. PubMed ID: 22182940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research in anxiety disorders: from the bench to the bedside.
    Garner M; Möhler H; Stein DJ; Mueggler T; Baldwin DS
    Eur Neuropsychopharmacol; 2009 Jun; 19(6):381-90. PubMed ID: 19327970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward an integrative model of the spectrum of mood, behavioral and personality disorders based on fear and anger traits: II. Implications for neurobiology, genetics and psychopharmacological treatment.
    Lara DR; Akiskal HS
    J Affect Disord; 2006 Aug; 94(1-3):89-103. PubMed ID: 16712943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan.
    Uchida H; Suzuki T; Mamo DC; Mulsant BH; Tsunoda K; Takeuchi H; Kikuchi T; Nakajima S; Nomura K; Tomita M; Watanabe K; Kashima H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):244-6. PubMed ID: 19175759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of psychotropic drugs in epilepsy: what every neurologist should know.
    Kanner AM
    Semin Neurol; 2008 Jul; 28(3):379-88. PubMed ID: 18777484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doctor's orders.
    Miller L
    Ment Health Today; 2009 Feb; ():34. PubMed ID: 19266657
    [No Abstract]   [Full Text] [Related]  

  • 13. [Anxiety and the mechanisms of action of anxiolytics].
    Marino A; Costa R
    Recenti Prog Med; 1993 Feb; 84(2):129-41. PubMed ID: 8096650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inadequate availability of pharmacological treatment for affective disorders in New Zealand.
    Porter RJ; Mulder RT
    N Z Med J; 2002 Feb; 115(1148):78-81. PubMed ID: 11913939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Merging the cognitive behavioral and psychopharmacological paradigms in comparative studies: controversies, issues, and some solutions.
    Gorman JM; Barlow DH; Ray S; Shear MK; Woods S
    Psychopharmacol Bull; 2001; 35(2):111-24. PubMed ID: 12397891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiety levels and related pharmacological drug treatment: a memorandum for the third millennium.
    Pasquini M; Berardelli I
    Ann Ist Super Sanita; 2009; 45(2):193-204. PubMed ID: 19636172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Calcium antagonistic actions of drugs used in treatment of affective disorders].
    Langosch JM; Walden J
    Fortschr Neurol Psychiatr; 1998 Dec; 66(12):570-9. PubMed ID: 9922929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Psychostimulants: a potential therapeutic alternative in mood and obsessive compulsive disorders (first part)].
    Samain V
    Rev Med Brux; 2003 Dec; 24(6):464-9. PubMed ID: 14748179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic assessment of herbal drugs in affective disorders.
    Sahoo S; S B
    Biomed Pharmacother; 2019 Jan; 109():1148-1162. PubMed ID: 30551365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.